Last updated: 2026-09-05 01:37:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cybin Inc. (HELP) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $12.21, with a market capitalisation of $873.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.76 to $14.35. This page covers its latest market performance, valuation, price trends and company information.
$873.18M | |
$11.71 | |
$14.35 | |
$3.76 | |
$11.77 | |
980.76K | |
-- | |
-- | |
$14.35 | |
$3.76 | |
-- | |
-- |
Cybin Inc. (HELP) last closed at $11.77 as of 2026-09-05 00:00:00, unchanged from the previous close of $11.77.
During the latest regular trading session, HELP traded between $3.76 and $14.35, with a volume of 980.76K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Cybin Inc. (HELP) moved from $11.97 to $12.21, representing a gain of 2.01% ($0.24).
The stock traded between $11.45 and $12.26 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.27 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 79.8%
HELP is currently trading at $12.21, placing it 79.8% of the way from its 52-week low of $3.76 to its 52-week high of $14.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
| Employees | 50 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cybin Inc. (HELP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.